前立腺肥大症（BPH）治療市場：世界の市場規模、シェア、動向分析、機会、予測レポート、2019-2029年

世界の前立腺肥大症（BPH）治療市場規模は2029年までに74億米ドルに達する見込み

世界の前立腺肥大症（BPH）治療市場は、世界中でBPHの有病率が増加していること、BPHになりやすい老年人口が増加していること、低侵襲治療の選択肢が進歩していることから、活況を呈しています。

大手戦略コンサルティング・市場調査会社のBlueWeave Consultingは最近の調査で、2022年の世界の前立腺肥大症（BPH）治療市場規模を59億7,797万米ドルと推定しました。2023年から2029年の予測期間において、世界の前立腺肥大症（BPH）治療市場規模は安定したCAGR 3.13％で成長し、2029年には73億8,199万米ドルに達するとBlueWeaveは予測しています。世界の前立腺肥大症（BPH）治療市場の主な成長促進要因には、利用可能な治療オプションに関する一般市民の意識の高まりが含まれます。また、経尿道的前立腺切除術（TURP）のイントロダクションなどの技術的進歩も、市場成長の推進に重要な役割を果たしています。TURPは内視鏡的電気外科処置であり、異常増殖による閉塞を緩和するために前立腺の一部を切除します。個人のヘルスケア支出能力の拡大と、特に新興諸国におけるヘルスケアインフラの顕著な改善は、市場の拡大をさらに推進すると予想されます。前立腺肥大症とそれに関連する泌尿器科疾患の有病率の増加は、市場成長の重要な促進要因です。炎症反応の上昇、交感神経の活動、酸化ストレスなどの要因は、特に肥満患者において前立腺肥大症の発症に寄与します。体内のホルモン変化も前立腺肥大とBPHの発症に関連しており、BPH治療薬の市場を拡大しています。また、未開拓の新興経済諸国は、ヘルスケアインフラの改善、アンメットヘルスケアニーズに対する需要の高まり、研究開発（R&D）への取り組みの増加により、市場開拓の大きなチャンスとなっています。したがって、このような側面が分析期間中の世界BPH市場の拡大を後押しすると予想されます。しかし、BPH治療手順に関連する高コストや、特定の治療オプションに関連する副作用や合併症は、予測期間中の市場全体の成長を抑制すると予想されます。

本レポートの詳細な分析により、世界の前立腺肥大症（BPH）治療市場の成長可能性、今後の動向、統計に関する情報を提供します。また、市場規模全体の予測を促進する要因も明らかにしています。本レポートは、世界の前立腺肥大症（BPH）治療市場の最新技術動向や、意思決定者が健全な戦略的意思決定を行うための業界洞察を提供することをお約束します。さらに、市場の成長促進要因・課題・競争力についても分析しています。

目次

第1章 調査の枠組み

第2章 エグゼクティブサマリー

第3章 世界の前立腺肥大症（BPH）治療市場に関する洞察

• 業界のバリューチェーン分析
• DROC分析
  • 成長の原動力
    • 世界的に前立腺肥大症の有病率が増加
    • 前立腺肥大症になりやすい高齢化人口の増加
    • 低侵襲治療の選択肢の進歩
  • 抑制要因
    • 前立腺肥大症の治療に伴う高額な費用
    • 特定の治療オプションに関連する副作用と合併症
  • 機会
    • 新しくてより効果的な治療選択肢の開発。
    • 研究開発への投資の増加。
  • 課題
    • 市場関係者間の熾烈な競合
    • 特定の地域では高度な治療技術の導入の遅れ
• 技術の進歩/最近の開発
• 規制の枠組み
• ポーターのファイブフォース分析

第4章 世界の前立腺肥大症（BPH）治療市場概要

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 療法別
    • 単剤療法
    • 併用薬物療法
  • 治療クラス別
    • アルファブロッカー
    • 5-α-レダクターゼ阻害剤
    • ホスホジエステラーゼ-5阻害剤
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋（APAC）
    • ラテンアメリカ（LATAM）
    • 中東およびアフリカ（MEA）

第5章 北米の前立腺肥大症（BPH）治療市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 療法別
  • 治療クラス別
  • 国別
    • 米国
    • カナダ

第6章 欧州の前立腺肥大症（BPH）治療市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 療法別
  • 治療クラス別
  • 国別
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • ベルギー
    • ロシア
    • オランダ
    • その他欧州

第7章 アジア太平洋の前立腺肥大症（BPH）治療市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 療法別
  • 治療クラス別
  • 国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリアとニュージーランド
    • インドネシア
    • マレーシア
    • シンガポール
    • ベトナム
    • APACのその他諸国

第8章 ラテンアメリカの前立腺肥大症（BPH）治療市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 療法別
  • 治療クラス別
  • 国別
    • ブラジル
    • メキシコ
    • アルゼンチン
    • ペルー
    • 中南米の残りの地域

第9章 中東およびアフリカの前立腺肥大症（BPH）治療市場

• 市場規模と予測、2019～2029年
  • 金額別
• 市場シェアと予測
  • 療法別
  • 治療クラス別
  • 国別
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • クウェート
    • 南アフリカ
    • ナイジェリア
    • アルジェリア
    • MEAの残りの部分

第10章 競合情勢

• 主要企業とその製品のリスト
• 世界の前立腺肥大症（BPH）治療市場シェア分析、2022年
• 経営パラメータ別競合ベンチマーキング
• 主要な戦略的展開（合併、買収、パートナーシップなど）

第11章 世界の前立腺肥大症（BPH）治療市場に対するCOVID-19感染症の影響

第12章 企業プロファイル（会社概要、財務マトリックス、競合情勢、主要な人材、主要な競合、連絡先住所、戦略的展望、 SWOT分析）

• Astellas Pharma Inc.
• Eli Lilly and Company
• GlaxoSmithKline plc
• AstraZeneca plc
• Johnson & Johnson
• Pfizer Inc.
• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic plc
• Urologix, LLC
• Teleflex Incorporated
• Olympus Corporation
• Merck & Co., Inc.
• Allergan plc
• Endo International plc
• Other Prominent Players

第13章 主要な戦略的推奨事項

第14章 調査手法

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Set to Touch USD 7.4 Billion by 2029.

Global benign prostatic hyperplasia (BPH) treatment market is flourishing, because of increasing prevalence of BPH across the world, growing geriatric population prone to BPH, and advancements in minimally invasive treatment options.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global benign prostatic hyperplasia (BPH) treatment market size at USD 5,977.97 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global benign prostatic hyperplasia (BPH) treatment market size to grow at a steady CAGR of 3.13% reaching a value of USD 7,381.99 million by 2029. Major growth drivers for the global benign prostatic hyperplasia (BPH) treatment market include an increasing awareness among the public regarding available treatment options. Technological advancements, such as the introduction of transurethral resection of the prostate (TURP), have also played a significant role in driving market growth. TURP is an endoscopic electrosurgical procedure that involves the removal of a portion of the prostate gland to alleviate blockage caused by abnormal growth. The expanding individual healthcare expenditure capacities and notable improvements in healthcare infrastructure, particularly in developing countries, are expected to further propel the market's expansion. The growing prevalence of benign prostatic hyperplasia and the associated urological conditions are significant drivers of market growth. Factors such as elevated inflammatory response, sympathetic nerve activity, and oxidative stress contribute to the development of BPH, particularly in obese patients. Hormonal changes in the body are also linked to prostate enlargement and the development of BPH, thereby expanding the market for BPH medications. Also, untapped emerging economies present significant opportunities for market development due to improved healthcare infrastructure, a growing demand for unmet healthcare needs, and increased efforts in research and development (R&D). Hence, such aspects are expected to boost the expansion of global BPH market during the period in analysis. However, high costs associated with BPH treatment procedures and adverse effects and complications associated with certain treatment options are anticipated to restrain the growth of overall market during the forecast period.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Overview:

Benign prostatic hyperplasia (BPH), commonly referred to as the enlargement of the prostate gland, tends to become more prevalent in aging men. An enlarged prostate gland can lead to urinary symptoms, such as urinary retention, and may also affect the bladder, urethra, or kidneys. Treatment options for BPH encompass a range of approaches, including prescription medications, active surveillance, monotherapy and combination therapy, phytotherapy, as well as minimally invasive and invasive surgeries. These procedures often involve the utilization of resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. Active surveillance serves as one of the primary treatment methods for BPH. This approach entails closely monitoring the condition without active intervention. Under the guidance of a urologist, regular monitoring of the BPH will take place, typically through annual physical examinations. The focus will be on identifying any new or worsening symptoms before considering further interventions. Additionally, lifestyle modifications, including dietary adjustments and exercise, are commonly recommended to prevent or manage symptoms. Active surveillance is typically suitable for men experiencing mild to moderate symptoms or those who are not significantly bothered by BPH symptoms. However, if symptoms worsen or new ones emerge, the healthcare provider may recommend transitioning to active therapy.

Impact of COVID-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market:

COVID-19 pandemic adversely affected global benign prostatic hyperplasia (BPH) treatment market. The healthcare system's focus on managing and containing the virus has resulted in a redirection of resources, affecting the diagnosis and treatment of non-emergency conditions, such as BPH. Delayed elective surgeries, reduced outpatient visits, and disruptions in the supply chain of medications and medical devices have impacted the market. Moreover, the economic impact of the pandemic has led to financial constraints for individuals, affecting their ability to seek timely BPH treatment. However, with the gradual resumption of healthcare services and the development of vaccination programs, the market recovered in the post-pandemic period, with a renewed emphasis on addressing the unmet needs of BPH patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - By Therapy:

By therapy, the global benign prostatic hyperplasia (BPH) treatment market is bifurcated into Mono Drug Therapy and Combination Drug Therapy segments. The combination drug therapy segment holds a higher market share in the global benign prostatic hyperplasia (BPH) treatment market, due to its enhanced efficacy and comprehensive approach. By combining medications with different mechanisms of action, combination therapy offers improved symptom relief and better outcomes compared to mono drug therapy. The synergistic effects of combined drugs further contribute to its popularity among healthcare providers and patients. Treatment guidelines and recommendations endorsing combination therapy, along with patient preferences for convenience, also drive its market dominance. Streamlining multiple medications into a single combination product enhances medication adherence and patient compliance. These factors collectively contribute to the prominence of combination drug therapy in the BPH treatment market.

Competitive Landscape:

Major players operating in the global benign prostatic hyperplasia (BPH) treatment market include: Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Benign Prostatic Hyperplasia (BPH) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Benign Prostatic Hyperplasia (BPH) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

2. Executive Summary

3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Insights

• 3.1. Industry Value Chain Analysis
• 3.2. DROC Analysis
  • 3.2.1. Growth Drivers
    • 3.2.1.1. Increasing prevalence of BPH globally.
    • 3.2.1.2. Growing ageing population prone to BPH.
    • 3.2.1.3. Advancements in minimally invasive treatment options.
  • 3.2.2. Restraints
    • 3.2.2.1. High costs associated with BPH treatment procedures
    • 3.2.2.2. Adverse effects and complications associated with certain treatment options
• 3.3. Opportunities
  • 3.3.1.1. Development of novel and more effective treatment options.
  • 3.3.1.2. Increasing investment in research and development.
  • 3.3.2. Challenges
    • 3.3.2.1. Intense competition among market players.
    • 3.3.2.2. Slow adoption of advanced treatment technologies in certain regions.
• 3.4. Technology Advancements/Recent Developments
• 3.5. Regulatory Framework
• 3.6. Porter's Five Forces Analysis
  • 3.6.1. Bargaining Power of Suppliers
  • 3.6.2. Bargaining Power of Buyers
  • 3.6.3. Threat of New Entrants
  • 3.6.4. Threat of Substitutes
  • 3.6.5. Intensity of Rivalry

4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

• 4.1. Market Size & Forecast, 2019-2029
  • 4.1.1. By Value (USD Million)
• 4.2. Market Share and Forecast
  • 4.2.1. By Therapy
    • 4.2.1.1. Mono drug therapy
    • 4.2.1.2. Combination drug therapy
  • 4.2.2. By Therapeutic Class
    • 4.2.2.1. Alpha blockers
    • 4.2.2.2. 5- alpha-reductase inhibitors
    • 4.2.2.3. Phosphodiesterase-5 inhibitors
    • 4.2.2.4. Others
  • 4.2.3. By Region
    • 4.2.3.1. North America
    • 4.2.3.2. Europe
    • 4.2.3.3. Asia Pacific (APAC)
    • 4.2.3.4. Latin America (LATAM)
    • 4.2.3.5. Middle East and Africa (MEA)

5. North America Benign Prostatic Hyperplasia (BPH) Treatment Market

• 5.1. Market Size & Forecast, 2019-2029
  • 5.1.1. By Value (USD Million)
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy
  • 5.2.2. By Therapeutic Class
  • 5.2.3. By Country
    • 5.2.3.1. United States
    • 5.2.3.1.1. By Therapy
    • 5.2.3.1.2. By Therapeutic Class
    • 5.2.3.2. Canada
    • 5.2.3.2.1. By Therapy
    • 5.2.3.2.2. By Therapeutic Class

6. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market

• 6.1. Market Size & Forecast, 2019-2029
  • 6.1.1. By Value (USD Million)
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy
  • 6.2.2. By Therapeutic Class
  • 6.2.3. By Country
    • 6.2.3.1. Germany
    • 6.2.3.1.1. By Therapy
    • 6.2.3.1.2. By Therapeutic Class
    • 6.2.3.2. United Kingdom
    • 6.2.3.2.1. By Therapy
    • 6.2.3.2.2. By Therapeutic Class
    • 6.2.3.3. Italy
    • 6.2.3.3.1. By Therapy
    • 6.2.3.3.2. By Therapeutic Class
    • 6.2.3.4. France
    • 6.2.3.4.1. By Therapy
    • 6.2.3.4.2. By Therapeutic Class
    • 6.2.3.5. Spain
    • 6.2.3.5.1. By Therapy
    • 6.2.3.5.2. By Therapeutic Class
    • 6.2.3.6. Belgium
    • 6.2.3.6.1. By Therapy
    • 6.2.3.6.2. By Therapeutic Class
    • 6.2.3.7. Russia
    • 6.2.3.7.1. By Therapy
    • 6.2.3.7.2. By Therapeutic Class
    • 6.2.3.8. The Netherlands
    • 6.2.3.8.1. By Therapy
    • 6.2.3.8.2. By Therapeutic Class
    • 6.2.3.9. Rest of Europe
    • 6.2.3.9.1. By Therapy
    • 6.2.3.9.2. By Therapeutic Class

7. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market

• 7.1. Market Size & Forecast, 2019-2029
  • 7.1.1. By Value (USD Million)
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy
  • 7.2.2. By Therapeutic Class
  • 7.2.3. By Country
    • 7.2.3.1. China
    • 7.2.3.1.1. By Therapy
    • 7.2.3.1.2. By Therapeutic Class
    • 7.2.3.2. India
    • 7.2.3.2.1. By Therapy
    • 7.2.3.2.2. By Therapeutic Class
    • 7.2.3.3. Japan
    • 7.2.3.3.1. By Therapy
    • 7.2.3.3.2. By Therapeutic Class
    • 7.2.3.4. South Korea
    • 7.2.3.4.1. By Therapy
    • 7.2.3.4.2. By Therapeutic Class
    • 7.2.3.5. Australia & New Zealand
    • 7.2.3.5.1. By Therapy
    • 7.2.3.5.2. By Therapeutic Class
    • 7.2.3.6. Indonesia
    • 7.2.3.6.1. By Therapy
    • 7.2.3.6.2. By Therapeutic Class
    • 7.2.3.7. Malaysia
    • 7.2.3.7.1. By Therapy
    • 7.2.3.7.2. By Therapeutic Class
    • 7.2.3.8. Singapore
    • 7.2.3.8.1. By Therapy
    • 7.2.3.8.2. By Therapeutic Class
    • 7.2.3.9. Vietnam
    • 7.2.3.9.1. By Therapy
    • 7.2.3.9.2. By Therapeutic Class
    • 7.2.3.10. Rest of APAC
    • 7.2.3.10.1. By Therapy
    • 7.2.3.10.2. By Therapeutic Class

8. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market

• 8.1. Market Size & Forecast, 2019-2029
  • 8.1.1. By Value (USD Million)
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy
  • 8.2.2. By Therapeutic Class
  • 8.2.3. By Country
    • 8.2.3.1. Brazil
    • 8.2.3.1.1. By Therapy
    • 8.2.3.1.2. By Therapeutic Class
    • 8.2.3.2. Mexico
    • 8.2.3.2.1. By Therapy
    • 8.2.3.2.2. By Therapeutic Class
    • 8.2.3.3. Argentina
    • 8.2.3.3.1. By Therapy
    • 8.2.3.3.2. By Therapeutic Class
    • 8.2.3.4. Peru
    • 8.2.3.4.1. By Therapy
    • 8.2.3.4.2. By Therapeutic Class
    • 8.2.3.5. Rest of LATAM
    • 8.2.3.5.1. By Therapy
    • 8.2.3.5.2. By Therapeutic Class

9. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market

• 9.1. Market Size & Forecast, 2019-2029
  • 9.1.1. By Value (USD Million)
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy
  • 9.2.2. By Therapeutic Class
  • 9.2.3. By Country
    • 9.2.3.1. Saudi Arabia
    • 9.2.3.1.1. By Therapy
    • 9.2.3.1.2. By Therapeutic Class
    • 9.2.3.2. UAE
    • 9.2.3.2.1. By Therapy
    • 9.2.3.2.2. By Therapeutic Class
    • 9.2.3.3. Qatar
    • 9.2.3.3.1. By Therapy
    • 9.2.3.3.2. By Therapeutic Class
    • 9.2.3.4. Kuwait
    • 9.2.3.4.1. By Therapy
    • 9.2.3.4.2. By Therapeutic Class
    • 9.2.3.5. South Africa
    • 9.2.3.5.1. By Therapy
    • 9.2.3.5.2. By Therapeutic Class
    • 9.2.3.6. Nigeria
    • 9.2.3.6.1. By Therapy
    • 9.2.3.6.2. By Therapeutic Class
    • 9.2.3.7. Algeria
    • 9.2.3.7.1. By Therapy
    • 9.2.3.7.2. By Therapeutic Class
    • 9.2.3.8. Rest of MEA
    • 9.2.3.8.1. By Therapy
    • 9.2.3.8.2. By Therapeutic Class

10. Competitive Landscape

• 10.1. List of Key Players and Their Offerings
• 10.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Analysis, 2022
• 10.3. Competitive Benchmarking, By Operating Parameters
• 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

• 12.1. Astellas Pharma Inc.
• 12.2. Eli Lilly and Company
• 12.3. GlaxoSmithKline plc
• 12.4. AstraZeneca plc
• 12.5. Johnson & Johnson
• 12.6. Pfizer Inc.
• 12.7. Abbott Laboratories
• 12.8. Boston Scientific Corporation
• 12.9. Medtronic plc
• 12.10. Urologix, LLC
• 12.11. Teleflex Incorporated
• 12.12. Olympus Corporation
• 12.13. Merck & Co., Inc.
• 12.14. Allergan plc
• 12.15. Endo International plc
• 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

• 14.1. Qualitative Research
  • 14.1.1. Primary & Secondary Research
• 14.2. Quantitative Research
• 14.3. Market Breakdown & Data Triangulation
  • 14.3.1. Secondary Research
  • 14.3.2. Primary Research
• 14.4. Breakdown of Primary Research Respondents, By Region
• 14.5. Assumptions & Limitations